Conversely, DLBCL patients with high-risk scores exhibited lower proportions of CD8+ T cells (P < 0.05), CD4+ memory activated T cells (P < 0.01), gamma delta T cells (P < 0.0001), Macrophages M1 (P < 0.05), and resting mast cells (P < 0.01) than those in DLBCL patients with low-risk scores. This evidence concerns the gene CD4 and diffuse large B-cell lymphoma.